# Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

> **NCT02227459** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 25 (actual)

## Conditions studied

- Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)

## Interventions

- **DRUG:** ND-L02-s0201 Injection

## Key facts

- **NCT ID:** NCT02227459
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227459, "Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02227459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*